On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for gastric cancer.
In the section labeled principles of systemic therapy for unresectable locally advanced, recurrent or metastatic disease, fam-trastuzumab deruxtecan-nxki was added as a category 2A recommendation for second-line or subsequent therapy for HER2-positive adenocarcinoma. Additionally, under other regimens, fluorouracil and irinotecan + ramucirumab was changed from a category 2B to a category 2A recommendation.
In the section for principles of systemic therapy regimens and dosing schedules, the dosing schedules for fluoropyrimidine and fam-trastuzumab deruxtecan-nxki were added. The dosing schedule for paclitaxel was revised to 80 mg/m2 IV weekly, cycled every 28 days.—Janelle Bradley
